HOLOGIC®

Empowering you

to make an impact through our comprehensive portfolio, partnership and performance.

The Hologic Diagnostics division is your dedicated partner—proudly offering comprehensive testing for women's health and infectious disease. Through innovative, scalable solutions, expansive support, and strong partnerships, we empower you to improve clinical outcomes for people everywhere, every day.

As your dedicated partner, we forge strong partnerships between laboratories, providers, societies and patients to support testing needs and help navigate the challenges of managing infectious diseases, including COVID-19.

Our comprehensive portfolio offers testing across multiple disease areas, along with scalable and flexible automation through Panther® Scalable Solutions that can meet unprecedented testing needs today and sustain growth into the future.

Women's Health

- CT/NG
- *Mycoplasma genitalium*
- *Trichomonas vaginalis*
- Bacterial vaginosis
- Candida vaginitis/ *Trichomonas vaginalis*
- HSV 1 & 2
- HPV
- HPV 16 18/45
- Group B Strep
- Zika Virus*

Infectious Disease

- HIV-1 Quant
- HIV-1 Qual Claim† ‡
- HCV Quant Dx
- HBV Quant
- Flu A/B/RSV
- Paraflu
- AdV/hMPV/RV
- SARS-CoV-2§
- Bordetella†
- GI Panel†

We empower you to be at the forefront of diagnostic testing through our commitment to innovation. This has allowed us to provide the most widely-used products on the market—including the Panther platform, which has been used to run **over 1 million COVID-19 tests every week across all 50 states.**

Delivering highly accurate test results when and where they're needed is critical to controlling the COVID-19 pandemic. Hologic is proud to be a leader in the fight against COVID-19.

* The Aptima® Zika Virus:
  - This test has not been FDA cleared or approved;
  - This test has been authorized by FDA under an EUA for use by authorized laboratories;
  - This test has been authorized only for the detection of RNA from Zika and the diagnosis of Zika virus infection, not for any other viruses or pathogens; and
  - This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C.§ 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

§ The Aptima and Panther Fusion® SARS-CoV-2 assays:
  - These tests have not been FDA cleared or approved;
  - These tests have been authorized by FDA under an EUA for use by authorized laboratories;
  - These tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and
  - These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.§ 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

† In Development and not for sale ‡ Seeking dual claim for the HIV-1 Quant assay.